Adam is a commercially-minded attorney with considerable experience of building, optimizing and defending patent portfolios.
Having previously managed an extensive patent portfolio at a multinational healthcare company, Adam is adept at developing harmonized, robust global IP strategies that complement the commercial goals of his clients and add value to their business.
European patent oppositions are a core aspect of Adam’s work. He has a wealth of knowledge in this area having represented clients at over 50 hearings before the European Patent Office both attacking and defending business-critical patents. Adam enjoys the challenging, dynamic and adversarial nature of the opposition process and has an established track record in achieving favourable outcomes for his clients.
Adam is dedicated to providing insightful and pragmatic advice to clients across a range of different industries and specializes in the field of medical technology and medical devices.
Chemistry with Medicinal Chemistry
PhD in Biochemistry and Environmental Metabolomics
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.